Mark Engel, CEO, Phagelux
19
Phagelux, Inc. Mark Engel, CEO Oct., 2016 Corporate Overview Creating Solutions for Bacterial Problems AgriHealth Division Animal Health Asia Investment Conference
-
Upload
kisaco-research -
Category
Business
-
view
114 -
download
0
Transcript of Mark Engel, CEO, Phagelux
Phagelux, Inc.
Mark Engel, CEO Oct., 2016
Corporate Overview
Creating Solutions for Bacterial Problems
AgriHealth Division
Animal Health Asia Investment Conference
Phagelux, Inc.
CON
TENTS
1
2
3
4
Corporate Strategy
Development Overview• AgriHealth• HumanHealth
Background on Science
Summary
Phagelux, Inc.
Background1
Phagelux, Inc.
Technology Overview
What is a bacteriophage/phage?
“Bacteriophage”• Definition “eats
bacteria” • Virus
• 100 times smaller than bacteria cells
• Host-specific
Bacteriaphage structure
Head
Sheath
Base Plate
Tail Fibers
Phagelux, Inc.
Technology Overview
Bacteriophage - "Continuous killing"
Adsorption Injection
ReplicationLysis
PackagingCell Wall
Bacteria
Lysin
Lysin - "One-time killing"
Lysin attack cell wall
Bacteria lysis
Bacteria
The Lytic Cycle
Phagelux, Inc.
The Problem, The Opportunity
Bacterial Resistance to Current Treatments
Negative Side Effects of Antibiotics
Overuse Creates Health Issues
Phagelux, Inc.
The Solution, The Science
Utilize Nature vs. NatureWhy is the Time Right for Phage Solutions
• manufacture efficiently and purely• rapidly identify the target bacteria• create effective cocktail solutions
Goal： Use bacteriophage and related technology to replace current anti-bacterials
AgriHealth
HumanHealth
Phagelux, Inc.
Corporate Strategy2
Phagelux, Inc.
2014
Corporate Strategy
Global Technolog
y Leadershi
p
US & China Production
Global sales
through partnershi
p
2015
China market by
direct sales
2016
Phagelux, Inc.
Development Overview3
Phagelux, Inc.
2013 2014 2015 2016 2017
FormationDec. 2013
Infrastructure Build Labs, teams, product development, initial partnerships, IP in-licensing
ExpansionManufacturing, initial registrations, initial sales, capital raise
InstitutionalizationERP system, public accountants, 12 to 15 product on market or in development
Public OfferingsAgriHealth – 2017/8HumanHealth – 2018/9
A Young but Maturing Company!
Phagelux, Inc.
Seasoned Management TeamInfrastructure
A Young but Maturing Company!
• Product development labs - Montreal, Salt Lake City, Nanjing, Wuhan
• Factories - Salt Lake City, Suzhou (AgriHealth scale Up), with additional scale up facilities in Nanjing and Montreal
• Products - 12 products under development, 9 in the AgriHealth division and 5 in the HumanHealth.
Phagelux, Inc.
AgriHealth
Phagelux, Inc.
Current Sales - OmniLytics
OmniLyticsA Phagelux Acquired
Subsidiary – Large scale non-GMP for AgriHealth
Products
Phagelux, Inc.
• AgriPhage: Biological control of bacterial spot and bacterial speck on tomatoes and peppers
• AgriPhage-CMM: Biological control for bacterial canker disease on tomato
Current Sales – US and China
Phagelux China – “Happy Shrimp”• $4 billion USD loss of shrimp farm
globally in 2015 – parahaemolyticus infection
• Water treatment product approved in China
OmniLytics - US market
Phagelux, Inc.
Program
Research
Candidate selection
Challenge trials
Clinical field trails
Regula-tory
Notes:• Excludes OmniLytics agricultural products• NJ-02-EMS regulatory approval already received for China for water
treatment
AgriHealth Lead Products – R & D
NJ-04-SM - Salmonella spp. – Food Processing AidFoodSafety
Animal HealthAnimalHealth
NJ-02-EMS - V. parahaemolyticus – EMS/APHNS Water Treatment + Feed AdditiveAqua
NJ-08-EE – Staphylococcus spp. – Greasy Pig
NJ-09-EM - Multiple – Sow Endometritis
Phagelux, Inc.
Summary4
Phagelux, Inc.
Summary
Products/Revenue
Labs
Manufacturing
Management Team
IPO Strategy
Technologies
Mark EngelCEO
Dr. Joey ZhouDirector of Business
m
CONTACT US
http://www.phagelux.com
